###begin article-title 0
###xml 141 146 141 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR4</italic>
Mutational Analysis of EGFR and Related Signaling Pathway Genes in Lung Adenocarcinomas Identifies a Novel Somatic Kinase Domain Mutation in FGFR4
###end article-title 0
###begin p 1
Conceived and designed the experiments: EM LF TM RW BS WP MZ MK IS JM MM AL YK DP VR HV. Performed the experiments: EM LF TM RW BS WP MZ MK IS JM MM AL YK GF SB DP VR HV. Analyzed the data: EM LF TM RW WP MZ MK JM MM AL YK GF SB VR HV. Contributed reagents/materials/analysis tools: EM LF TM RW BS WP MZ MK JM MM AL YK GF SB VR HV. Wrote the paper: EM LF RW WP MZ MK JM MM AL YK VR HV.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 134 176 134 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR, HER2/ERBB2, HER4/ERBB4, PIK3CA, BRAF</italic>
###xml 182 186 182 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
Fifty percent of lung adenocarcinomas harbor somatic mutations in six genes that encode proteins in the EGFR signaling pathway, i.e., EGFR, HER2/ERBB2, HER4/ERBB4, PIK3CA, BRAF, and KRAS. We performed mutational profiling of a large cohort of lung adenocarcinomas to uncover other potential somatic mutations in genes of this signaling pathway that could contribute to lung tumorigenesis.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 728 744 728 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR, KRAS, BRAF</italic>
###xml 750 756 750 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 850 855 850 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR4</italic>
###xml 904 909 904 909 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR4</italic>
###xml 981 986 981 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERBB2</italic>
###xml 1070 1075 1070 1075 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR4</italic>
We analyzed genomic DNA from a total of 261 resected, clinically annotated non-small cell lung cancer (NSCLC) specimens. The coding sequences of 39 genes were screened for somatic mutations via high-throughput dideoxynucleotide sequencing of PCR-amplified gene products. Mutations were considered to be somatic only if they were found in an independent tumor-derived PCR product but not in matched normal tissue. Sequencing of 9MB of tumor sequence identified 239 putative genetic variants. We further examined 22 variants found in RAS family genes and 135 variants localized to exons encoding the kinase domain of respective proteins. We identified a total of 37 non-synonymous somatic mutations; 36 were found collectively in EGFR, KRAS, BRAF, and PIK3CA. One somatic mutation was a previously unreported mutation in the kinase domain (exon 16) of FGFR4 (Glu681Lys), identified in 1 of 158 tumors. The FGFR4 mutation is analogous to a reported tumor-specific somatic mutation in ERBB2 and is located in the same exon as a previously reported kinase domain mutation in FGFR4 (Pro712Thr) in a lung adenocarcinoma cell line.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
This study is one of the first comprehensive mutational analyses of major genes in a specific signaling pathway in a sizeable cohort of lung adenocarcinomas. Our results suggest the majority of gain-of-function mutations within kinase genes in the EGFR signaling pathway have already been identified. Our findings also implicate FGFR4 in the pathogenesis of a subset of lung adenocarcinomas.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 92 95 92 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Jemal1">[1]</xref>
Lung cancer is the leading cause of cancer-related death in the United States and worldwide [1]. Despite recent advances in the treatment of lung cancer, the overall 5-year survival in the United States remains only 15%, highlighting the need for novel treatment strategies.
###end p 9
###begin p 10
###xml 381 384 381 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Gabrielson1">[2]</xref>
Lung cancers are currently classified into two major groups depending on histology: small cell lung cancer and non-small cell lung cancer (NSCLC). The latter is comprised of three different subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. The incidence of the adenocarcinoma subtype has been rising and now accounts for >50% of all cases of lung cancer [2]. Standard treatment for metastatic lung cancer involves empiric cytotoxic chemotherapy.
###end p 10
###begin p 11
###xml 376 380 376 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 542 546 542 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 546 549 546 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Lynch1">[3]</xref>
###xml 550 553 550 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Pao1">[5]</xref>
###xml 600 604 600 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 691 694 691 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Pao2">[6]</xref>
###xml 695 698 695 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Giaccone1">[8]</xref>
###xml 808 812 808 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 825 828 825 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Pao3">[9]</xref>
###xml 830 834 830 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Kobayashi1">[10]</xref>
###xml 1100 1108 <span type="species:ncbi:9606">patients</span>
In order to develop specific therapies based upon the genetic makeup of individual NSCLC tumors, we (the Lung Cancer Oncogenome Group at Memorial Sloan-Kettering Cancer Center (MSKCC)) and others have sought to define clinically relevant molecular subsets of lung cancer. For example, we and others have shown that tumors highly sensitive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (i.e. gefitinib or erlotinib) often contain dominant mutations in exons which encode a portion of the tyrosine kinase (TK) domain of EGFR[3]-[5]. Conversely, tumors with somatic mutations in KRAS, which encodes a GTPase downstream of EGFR, are resistant to therapy with these drugs [6]-[8]. Furthermore, about half of tumors with acquired resistance to these drugs display a second-site mutation in EGFR (Thr790Met) [9], [10]. Taken together, these data suggest that molecularly defined subgroups of lung cancer indeed exist and can be used to predict sensitivity and resistance to gefitinib and erlotinib. Clinicians in the future may be able to prescribe additional targeted therapies for patients with NSCLC based upon specific molecular characteristics.
###end p 11
###begin p 12
###xml 88 92 88 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 97 101 97 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 225 235 213 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2/ERBB2</italic>
###xml 271 275 247 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Stephens1">[11]</xref>
###xml 277 281 253 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Shigematsu1">[12]</xref>
###xml 286 290 262 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER4</italic>
###xml 323 327 287 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Soung1">[13]</xref>
###xml 346 352 310 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 379 383 331 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Samuels1">[14]</xref>
###xml 417 421 369 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 457 461 397 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Naoki1">[15]</xref>
###xml 462 466 402 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Davies1">[17]</xref>
###xml 555 561 495 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 572 576 512 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Endoh1">[18]</xref>
###xml 578 582 518 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Kawano1">[19]</xref>
###xml 786 790 726 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Shigematsu2">[20]</xref>
At least six EGFR signaling pathway genes have been found to be mutated in NSCLC. While EGFR and KRAS mutations are detected in approximately10% and 20% of NSCLCs, respectively, somatic mutations have also been identified in HER2/ERBB2 (approximately2%; exons 19 and 20) [11], [12] and HER4 (approximately2%, exons 20, 23) [13], the lipid kinase PIK3CA (approximately4%; exon 9) [14], and the serine/threonine kinase BRAF (approximately2%; exons 11 and 15) [15]-[17]. Most of these alterations have been found to be gain-of-function mutations. Except for PIK3CA mutations [18], [19], mutations in one of the other five genes are rarely found to be accompanied by a mutation in any of the remaining four, suggesting that they may have functionally equivalent roles in lung tumorigenesis [20]. All of these mutations are predominantly found in tumors with adenocarcinoma histology.
###end p 12
###begin p 13
###xml 463 516 463 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERBB1-4, PIK3CA, AKT1-3, FRAP1, RPS6K1-2, RAS (K-, N-</italic>
###xml 522 524 522 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H-</italic>
###xml 527 542 527 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RAF (A-, B-, C-</italic>
###xml 545 553 545 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAP2K1-2</italic>
###xml 559 567 559 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAPK-1-3</italic>
###xml 672 679 672 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR1-4</italic>
###xml 799 803 799 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Clark1">[21]</xref>
###xml 804 808 804 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Zhao1">[23]</xref>
###xml 722 727 <span type="species:ncbi:10090">mouse</span>
To uncover other potential gain-of-function somatic mutations that could have biological and clinical relevance in lung cancer, we performed mutational profiling of a large cohort of lung tumors, mostly adenocarcinomas. Because multiple genes that encode proteins in the EGFR signaling pathway have been found to be mutated in lung adenocarcinomas, we specifically sought to identify potential gain-of-function mutations in gene families in this pathway, i.e. in ERBB1-4, PIK3CA, AKT1-3, FRAP1, RPS6K1-2, RAS (K-, N-, and H-), RAF (A-, B-, C-), MAP2K1-2, and MAPK-1-3. We extended our studies to include other members of the MAP2K and MAPK gene families. We also examined FGFR1-4, because overexpression of FGF ligands in mouse lung epithelia leads to alveolar type II cell hyperplasia and adenomas [21]-[23]. All 39 genes have been reported to be expressed in mammalian lung tissues.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
Tissue procurement
###end title 15
###begin p 16
###xml 634 638 626 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 663 666 655 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Pao1">[5]</xref>
###xml 77 85 <span type="species:ncbi:9606">patients</span>
Resected tumor and matched normal adjacent lung specimens were obtained with patients' consent from the Memorial Sloan-Kettering Cancer Center (MSKCC) lung cancer tissue bank via a protocol approved by the Institutional Review Board (protocol #92-055). At the time of resection, samples were snap-frozen in the operating room in liquid nitrogen and then stored at minus 80degreesC until the time of use. Specimens were reviewed by a single pathologist (MFZ) for >/=70% tumor content and for histological verification. Clinical information was obtained from existing institutional databases. Some data regarding the mutation status of EGFR was previously reported [5].
###end p 16
###begin title 17
Mutational profiling
###end title 17
###begin p 18
Tumors selected for analyses were enriched for lung adenocarcinomas but were otherwise randomly selected, based upon availability of tissue. Squamous cell carcinomas were included to fill-in otherwise empty plate wells. No large cell carcinomas were studied.
###end p 18
###begin p 19
DNA was extracted from tumors using a kit (DNeasy, Qiagen) or standard phenol extraction. Whole genome amplification (WGA) was performed by Qiagen. High-throughput (96-well plate) bidirectional dideoxynucleotide sequencing of PCR-amplified gene products was performed at the Genome Sequencing Center (Washington University in St. Louis) as per standard protocol (). The primer list can be found at: id = 7.
###end p 19
###begin p 20
###xml 10 14 10 14 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Nickerson1">[24]</xref>
###xml 28 32 28 32 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Chen1">[25]</xref>
###xml 239 264 239 264 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">see Supplemental Table S1</bold>
###xml 239 264 239 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0000426.s001"><bold>see Supplemental Table S1</bold></xref>
PolyPhred [24] and PolyScan [25] software were used to generate an initial "automated" report of sequence variations. Tumor sequences were compared against reference sequences listed in the NCBI (RefSeq) database for each respective gene (see Supplemental Table S1). After visual inspection of the individual forward and reverse chromatograms for confirmation of non-synonymous sequence variations and insertions or deletions (including duplications), a "manual review" list of potential nucleotide changes was produced. Synonymous variants and those with corresponding dbSNP () entries were also excluded.
###end p 20
###begin title 21
Mutation verification
###end title 21
###begin p 22
###xml 372 394 372 394 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Supplemental Tables S1</bold>
###xml 372 394 372 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0000426.s001"><bold>Supplemental Tables S1</bold></xref>
###xml 394 401 394 401 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> and S2</bold>
###xml 394 401 394 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0000426.s002"><bold> and S2</bold></xref>
###xml 741 743 707 709 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">96</sub>
Putative kinase domain mutations listed in the manual report were subsequently verified at MSKCC by bidirectional sequence analysis of a separate individual PCR product. Variants were deemed somatic if they were found to be absent in matched normal tissue. Primers were designed to detect each individual mutation, using each respective reference sequence and Vector NTI (Supplemental Tables S1 and S2). All PCR reactions were performed with HotStarTaq Master Mix Kit (Qiagen, Valencia, California), using standard conditions (95degreesCx15 min; 95degreesCx30 s, 60degreesCx30 s, 72degreesCx60 s, for 36 cycles, then 72degreesC for 5 minutes, 50 microl reactions). PCR products were purified with a MultiScreen Resist vacuum manifold and PCR96 Cleanup Plates (Millipore). Sequencing reactions were performed using Applied Biosystems Version 3.1 Big Dye Terminator chemistry and analyzed on an Applied Biosystems 3730 Sequencer.
###end p 22
###begin title 23
Development of "Mutagrator" - a mutation interpretation tool for tyrosine kinases
###end title 23
###begin p 24
###xml 604 608 592 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Maglott1">[26]</xref>
###xml 718 722 706 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Wheeler1">[27]</xref>
###xml 771 775 759 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Chenna1">[28]</xref>
###xml 958 962 946 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-MarchlerBauer1">[29]</xref>
###xml 1197 1201 1185 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Forbes1">[30]</xref>
###xml 535 540 <span type="species:ncbi:9606">human</span>
To support the interpretation of putative kinase domain mutations, we created a prototype mutation interpretation tool for tyrosine kinases (TKs), called "Mutagrator", located at approximatelylash/mutagrator/ (freely available to the research community). Mutagrator is a software program which takes curated mutation data from the literature and displays it in the context of a master protein (chosen by the user) and a protein-registered TK multiple domain alignment. In order to create the multiple alignment, we first retrieved 108 human TK gene records from EntrezGene by querying for domain cd00192 [26]. We then extracted TK domains from all 168 protein isoforms corresponding to these genes from Entrez Protein [27], aligned the domains using the ClustalW program [28], and added additional feature information, including ATP binding residues, activation loop, catalytic loop and substrate binding site boundaries from Conserved Domain Database (CDD) [29]. All input and output files are available on the Mutagrator website. Currently, curated mutation data is ingested from the Catalogue of Somatic Mutations in Cancer (COSMIC), which was created and is maintained by the Sanger Institute [30]. Collected data includes mutation (amino acid change and position), mutation type (point, insertion, deletion, complex), involved gene, tissue type, cancer type and published source. The version of the database used in this study (v20) consisted of about 30,000 individual mutations in about 1,300 genes, and corresponding to about 3,300 distinct mutations. From these data, Mutagrator produced interlinked, static HTML webpages of two types: master protein pages (for each protein in the TK domain alignment with mutations), and detailed mutation pages (for each protein residue position).
###end p 24
###begin title 25
Results
###end title 25
###begin p 26
###xml 302 323 302 323 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Supplemental Table S3</bold>
###xml 302 323 302 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0000426.s003"><bold>Supplemental Table S3</bold></xref>
###xml 371 392 371 392 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Supplemental Table S1</bold>
###xml 371 392 371 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0000426.s001"><bold>Supplemental Table S1</bold></xref>
We screened coding sequences from 39 genes for mutations in genomic DNA from a total of 261 resected, clinically annotated non-small cell lung cancer (NSCLC) specimens. 90% of tumors were adenocarcinomas, and 10% were squamous cell carcinomas. Clinical characteristics of examined tumors are listed in Supplemental Table S3, and the exonic coverage of genes is listed in Supplemental Table S1.
###end p 26
###begin p 27
###xml 244 274 244 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR, HER2, HER4, KRAS, PIK3CA</italic>
###xml 280 284 280 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 284 285 284 285 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 285 293 285 293 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1</bold>
###xml 285 293 285 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000426-g001"><bold>Figure 1</bold></xref>
###xml 293 294 293 294 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 313 325 313 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER3, MAP2K4</italic>
###xml 331 338 331 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR1-4</italic>
###xml 338 339 338 339 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 339 347 339 347 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1</bold>
###xml 339 347 339 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000426-g001"><bold>Figure 1</bold></xref>
###xml 347 348 347 348 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 467 468 467 468 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 468 476 468 476 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1</bold>
###xml 468 476 468 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000426-g001"><bold>Figure 1</bold></xref>
###xml 476 477 476 477 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 519 520 519 520 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 520 528 520 528 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1</bold>
###xml 520 528 520 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000426-g001"><bold>Figure 1</bold></xref>
###xml 528 529 528 529 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 775 779 775 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Ewing1">[31]</xref>
Due to logistical reasons, the mutational analysis was performed in two partially overlapping groups. We first examined genomic DNAs from 217 tumors for mutations in a set of core genes previously reported to harbor mutations in NSCLC, i.e. in EGFR, HER2, HER4, KRAS, PIK3CA, and BRAF(Figure 1). We also profiled HER3, MAP2K4, and FGFR1-4(Figure 1). We then examined 93 WGA-treated DNA tumor samples for mutations in EGFR pathway genes and a set of exploratory genes (Figure 1). Ten genes were sequenced in both groups (Figure 1) to maximize the number of tumors sequenced for the core genes. Eighty percent of the sequence reads in the WGA-treated specimens had a Phred quality score of at least 20 (data not shown), suggesting that most base-calling had an accuracy of 99% [31].
###end p 27
###begin p 28
###xml 44 51 44 51 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">methods</xref>
###xml 197 198 197 198 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 198 206 198 206 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</bold>
###xml 198 206 198 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000426-g002"><bold>Figure 2</bold></xref>
###xml 212 233 212 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0000426.s001">Supplemental Table S1</xref>
###xml 206 234 206 234 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">, and <xref ref-type="supplementary-material" rid="pone.0000426.s001">Supplemental Table S1</xref>)</bold>
Automatic and manual sequence analyses (see methods) identified 239 putative non-synonymous sequence variations, comprised of 174 different types of variants that differed from published sequences (Figure 2, and Supplemental Table S1). To focus our efforts, we concentrated on further examining the 22 variants (6 types) found in 3 RAS family genes and the 135 variants (99 types) found within exons encoding kinase domains of kinases. The 82 non-kinase domain variants (69 distinct types) have not yet been examined, although none occur at a frequency higher than 2%.
###end p 28
###begin p 29
###xml 50 53 50 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RAS</italic>
###xml 115 119 115 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 135 139 135 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HRAS</italic>
###xml 172 195 172 195 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(Supplemental Table S4)</bold>
###xml 172 195 172 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0000426.s004"><bold>(Supplemental Table S4)</bold></xref>
###xml 215 219 215 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 382 386 382 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 416 417 416 417 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 417 424 417 424 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1</bold>
###xml 417 424 417 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000426-t001"><bold>Table 1</bold></xref>
###xml 424 425 424 425 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
We confirmed 21 of the sequence variations in the RAS family. 20 were somatic (all in codons 12 or 13 of exon 2 of KRAS), while one in HRAS was found in matched normal DNA (Supplemental Table S4). The prevalence of KRAS mutations in our cohort of lung adenocarcinomas was 12% (20/173). All confirmed somatic mutations were found in adenocarcinomas except for a Gly12Asp mutation in KRAS in a squamous cell carcinoma (Table 1).
###end p 29
###begin p 30
###xml 189 212 189 212 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(Supplemental Table S4)</bold>
###xml 189 212 189 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0000426.s004"><bold>(Supplemental Table S4)</bold></xref>
###xml 333 356 333 356 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(Supplemental Table S4)</bold>
###xml 333 356 333 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0000426.s004"><bold>(Supplemental Table S4)</bold></xref>
###xml 479 489 479 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR, BRAF</italic>
###xml 495 501 495 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 501 524 501 524 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(Supplemental Table S4)</bold>
###xml 501 524 501 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0000426.s004"><bold>(Supplemental Table S4)</bold></xref>
###xml 544 554 544 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR, BRAF</italic>
###xml 560 566 560 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 743 750 743 750 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1</bold>
###xml 743 750 743 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000426-t001"><bold>Table 1</bold></xref>
###xml 756 762 756 762 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 815 819 815 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 880 881 880 881 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 881 888 881 888 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 881 888 881 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000426-t002"><bold>Table 2</bold></xref>
###xml 888 889 888 889 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
67 of the 135 kinase domain sequence variations were confirmed by analysis of sequence tracings from an independent PCR isolate. 48 variants were also found in corresponding normal samples (Supplemental Table S4). Two were of uncertain significance, because we were unable to obtain a PCR product from DNA from matched normal tissue (Supplemental Table S4). Of the remaining 17 confirmed non-synonymous somatic variants, 16 were found in genes known to be mutated in NSCLC, i.e. EGFR, BRAF, and PIK3CA(Supplemental Table S4). The prevalence of EGFR, BRAF, and PIK3CA mutations in lung adenocarcinomas was 6 (13/234), <1 (1/156), and 2% (2/132), respectively. Clinical characteristics of all tumors containing somatic mutations can be found in Table 1. One PIK3CA mutation was found in a tumor that also contained a KRAS mutation. No other tumor had more than one somatic mutation (Table 2).
###end p 30
###begin p 31
###xml 149 154 149 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR4</italic>
###xml 154 155 154 155 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 155 163 155 163 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3</bold>
###xml 155 163 155 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000426-g003"><bold>Figure 3</bold></xref>
###xml 163 164 163 164 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 353 354 353 354 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 354 362 354 362 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4</bold>
###xml 354 362 354 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000426-g004"><bold>Figure 4</bold></xref>
###xml 362 363 362 363 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 393 394 393 394 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 394 402 394 402 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4</bold>
###xml 394 402 394 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000426-g004"><bold>Figure 4</bold></xref>
###xml 408 415 408 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">methods</xref>
###xml 415 416 415 416 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 498 503 498 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERBB2</italic>
###xml 516 520 516 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Stephens1">[11]</xref>
###xml 608 609 608 609 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 609 617 609 617 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4</bold>
###xml 609 617 609 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000426-g004"><bold>Figure 4</bold></xref>
###xml 617 618 617 618 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 660 665 660 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR4</italic>
###xml 832 833 832 833 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 833 840 833 840 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 833 840 833 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000426-t002"><bold>Table 2</bold></xref>
###xml 840 841 840 841 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
In one lung adenocarcinoma specimen from a current smoker, we found a somatic heterozygous G to A mutation at nucleotide position 2041 in exon 16 of FGFR4(Figure 3). This mutation would lead to substitution of lysine for glutamic acid at position 681 (Glu681Lys), 51 amino acids downstream of the highly conserved DFG motif found in all protein kinases (Figure 4). Using our "Mutagrator tool" (Figure 4; see methods), we determined that an analogous mutation has been reported in a glioblastoma in ERBB2 (Glu914Lys) [11]. Moreover, the glutamic acid at position 681 is highly conserved among various kinases (Figure 4). The biological significance of the lung FGFR4 mutation remains to be determined experimentally. In total, this mutation was found in 1 of 158 tumors. We did not identify any other somatic mutations in this tumor (Table 2).
###end p 31
###begin title 32
Discussion
###end title 32
###begin p 33
###xml 410 413 410 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Paez1">[4]</xref>
###xml 604 608 604 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Davies2">[32]</xref>
We report a comprehensive sequencing study of major genes in a specific signaling pathway in a sizeable cohort of lung adenocarcinoma tumor specimens. Previous large-scale mutational profiling studies of lung cancer have examined either only the exons encoding the activation loops of receptor tyrosine kinase (RTK) genes (47 of 58 RTK genes) in 119 primary NSCLCs, of which 70 (59%) were lung adenocarcinomas [4], or the coding sequences of 518 protein kinases in a relatively limited number of samples, i.e. 26 primary lung neoplasms (7 adenocarcinomas) and seven cancer cell lines (6 adenocarcinomas) [32]. Here, we examined a total of 261 tumor samples, predominantly adenocarcinomas, specifically for genetic alterations in genes encoding major signaling proteins in the EGFR signaling pathway. We also determined the status of a select set of other genes potentially relevant to lung tumorigenesis.
###end p 33
###begin p 34
###xml 82 99 82 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR, KRAS, BRAF,</italic>
###xml 104 110 104 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 110 113 110 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Lynch1">[3]</xref>
###xml 114 117 114 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Pao1">[5]</xref>
###xml 119 123 119 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Stephens1">[11]</xref>
###xml 124 128 124 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Davies1">[17]</xref>
###xml 253 257 253 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 262 266 262 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 450 454 450 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Chen1">[25]</xref>
###xml 501 505 501 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 509 513 509 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER4</italic>
###xml 679 683 679 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
Most of the somatic mutations we found have been reported, including mutations in EGFR, KRAS, BRAF, and PIK3CA[3]-[5], [11]-[17]. The relative distribution of these mutations in our lung adenocarcinomas matches that observed by others. The frequency of EGFR and KRAS mutations was slightly lower than other published series, possibly because the mutation detection software that we used went through various stages of development during this project [25]. We did not identify any somatic mutations in HER2 or HER4. However, one of two variants of uncertain significance (due to inability to PCR amplify a gene product from matched normal DNA) was located in the kinase domain of HER2 (Arg784Cys) and has not been previously reported.
###end p 34
###begin p 35
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR4</italic>
###xml 191 196 191 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERBB2</italic>
###xml 221 225 221 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Stephens1">[11]</xref>
###xml 423 427 423 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Mohammadi1">[33]</xref>
###xml 1060 1061 1060 1061 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 1061 1069 1061 1069 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5</bold>
###xml 1061 1069 1061 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000426-g005"><bold>Figure 5</bold></xref>
###xml 1069 1070 1069 1070 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
We did find a novel mutation (Glu681Lys) in the kinase domain (exon 16) of FGFR4 in 1 of 158 tumors. This mutation is analogous to the previously reported Glu914Lys kinase domain mutation in ERBB2 found in a glioblastoma [11]. Glu681 is highly conserved region among various kinases, downstream of the DFG motif. Based on the crystal structure of the related family member FGFR1 tyrosine kinase domain (PDB accession 1FGK) [33], the analogous residue (Glu692) appears in close proximity to Ala626 in the TK catalytic loop and Arg661 in the TK activation loop. Since Glu692 is strongly positively charged and Arg661 is strongly negatively charged, the close spatial proximity of these two residues would likely lead to a strong ionic bond and therefore may be functionally important. Extrapolating back to FGFR4, we propose that the Glu681Lys mutation may alter the functional properties of the TK catalytic domain by reversing the charge of residue 681, potentially disrupting an ionic bond with residue Arg650, and thereby disrupting normal function of FGFR4 (Figure 5).
###end p 35
###begin p 36
###xml 302 306 302 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Eswarakumar1">[34]</xref>
###xml 432 436 432 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Clark1">[21]</xref>
###xml 437 441 437 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Zhao1">[23]</xref>
###xml 575 580 575 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR4</italic>
###xml 593 597 593 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Davies2">[32]</xref>
###xml 634 639 634 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR4</italic>
###xml 779 784 779 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR4</italic>
###xml 937 942 937 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR1</italic>
###xml 947 952 947 952 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
###xml 994 999 994 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR1</italic>
###xml 1004 1009 1004 1009 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
###xml 1163 1167 1163 1167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR</italic>
###xml 1292 1296 1292 1296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Eswarakumar1">[34]</xref>
###xml 1371 1376 1371 1376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR4</italic>
###xml 344 349 <span type="species:ncbi:10090">mouse</span>
###xml 1212 1217 <span type="species:ncbi:9606">human</span>
FGFR4 is a monomeric receptor protein tyrosine kinase possessing three immunoglobulin-like domains in the extracellular region. The protein is one of four high-affinity receptors for multiple members of the FGF family of ligands that evoke angiogenic, mitogenic, and differentiation responses in cells [34]. Such ligands, when overexpressed in mouse lung epithelia, stimulate alveolar type II cell hyperplasia and adenoma formation [21]-[23]. Interestingly, Davies et al have reported that a lung adenocarcinoma cell line also harbors a non-synonymous mutation in exon 16 of FGFR4 - Pro672Thr [32]. [The Davies et al paper referenced FGFR4 transcript variant 2; we referenced variant 1, so the equivalent mutation would be Pro712Thr.] Collectively, these data suggest a role for FGFR4 mutations in a subset of lung adenocarcinomas. The Sanger group also found two other somatic mutations in genes that encode the related family members, FGFR1 and FGFR2, in lung cancer specimens. The described FGFR1 and FGFR2 mutations occur outside the kinase domain, but in identical positions to activating germline mutations known to predispose to skeletal dysplasias. Other FGFR gene alterations have also been reported in human cancers, although rarely in exons encoding the kinase domain (reviewed in [34]). We plan to characterize the functional consequences of the two reported FGFR4 mutations and determine their prevalence in independent lung and other tumor specimen banks.
###end p 36
###begin p 37
###xml 137 154 137 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RPS6KA1-6, MAP2K3</italic>
###xml 160 166 160 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAP2K7</italic>
###xml 668 672 668 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Bredel1">[35]</xref>
###xml 674 678 674 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Paez2">[36]</xref>
###xml 733 737 733 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 741 745 741 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1524 1528 1512 1516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000426-Sjoblom1">[37]</xref>
This study has some potential limitations. First, we examined only 39 genes. We did not sequence all related gene family members such as RPS6KA1-6, MAP2K3, and MAP2K7. This study also did not seek potential mutations in genes encoding adaptor proteins or phosphatases that might affect the ERBB signaling pathway. Second, WGA could have skewed the results by selectively amplifying DNA from normal rather than tumor tissue. However, evaluation of data from multiple assays has established that base-calling discrepancies between amplified and unamplified samples are minimal and not significantly different than that observed after re-sequencing non-amplified samples [35], [36]. Consistent with this, in all cases where we found an EGFR or KRAS mutation in the original non-WGA-treated sample, we also detected the same mutation in the corresponding WGA-treated sample (n = 14; data not shown). Finally, in this initial study, we restricted our verification studies to non-synonymous variants in the exons encoding kinase domains, in view of the clinical significance of known somatic mutations in kinase domains. The 69 types of non-kinase domain sequence variations we identified are currently undergoing confirmation. Nevertheless, the prevalence thus far of non-synonymous somatic mutations per megabase of tumor sequenced in this study was 4.1 (37 total mutations/9Mb). This rate is slightly higher than that found by others in a mutational analysis of approximately13,000 genes in 11 colorectal and 11 breast cancers [37].
###end p 37
###begin p 38
This study represents an early step towards an understanding of the lung cancer oncogenome. Our results suggest that the majority of gain-of-function mutations within kinase genes in the EGFR signaling pathway may have been identified. We await results from the NCI/NHGRI-sponsored "technical demonstration project" - a pilot project for The Cancer Genome Atlas initiative, in which approximately 200 highly-curated lung adenocarcinomas are being analyzed for chromosomal gains and losses simultaneously with mutational profiling of about 1000 genes thought to be relevant to lung tumorigenesis. Efforts such as these should contribute towards the identification of the full spectrum of somatic mutations found in lung adenocarcinomas.
###end p 38
###begin title 39
Supporting Information
###end title 39
###begin p 40
Gene, GenBank accession number, and exonic coverage of genes sequenced in this study.
###end p 40
###begin p 41
(0.06 MB DOC)
###end p 41
###begin p 42
Click here for additional data file.
###end p 42
###begin p 43
List of primers used to verify putative variants.
###end p 43
###begin p 44
(0.15 MB DOC)
###end p 44
###begin p 45
Click here for additional data file.
###end p 45
###begin p 46
###xml 412 420 410 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000426-g001">Figure 1</xref>
###xml 28 36 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of patients whose tumors were analyzed. Group 1 was used for sequencing the "core" genes. Group 2 was used for sequencing the "exploratory" genes. Some tumors and genes overlapped between the two groups. Smoking history is defined as never smokers (<100 lifetime cigarettes), former smokers (quit >/=1 year prior to diagnosis), or current (quit <1 year prior to diagnosis). See text and Figure 1 for more detail. 1Adeno includes adenocarcinoma with bronchioalveolar features (n = 79, n = 27 for Group 1 and 2, respectively). Abbreviations: Adeno, adenocarcinoma; SCC, squamous cell carcinoma.
###end p 46
###begin p 47
(0.04 MB DOC)
###end p 47
###begin p 48
Click here for additional data file.
###end p 48
###begin p 49
###xml 80 88 80 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000426-g002">Figure 2</xref>
List of variants verified. Group headings correspond to groups in bottom row of Figure 2. Variants found in normal tissue did not have an existing entry in dbSNP. 1A total of 5 EGFR mutations (exon 19 del, n = 1: exon 21 L858R, n = 4) have been previously reported (5). 2Variants with high frequency were not verified in all samples. If a variant was also found in DNA from five matched normals, no further samples were verified. Abbreviations: del, deletion; dup, duplication.
###end p 49
###begin p 50
(0.08 MB DOC)
###end p 50
###begin p 51
Click here for additional data file.
###end p 51
###begin p 52
We thank the Lung Cancer Oncogenome Group at MSKCC for helpful discussions; Katerina Politi and Charles Sawyers for critical reading of the manuscript; and Dhananjay Chitale and Marc Ladanyi for help with DNA specimen extraction.
###end p 52
###begin title 53
References
###end title 53
###begin article-title 54
Cancer statistics, 2006.
###end article-title 54
###begin article-title 55
Worldwide trends in lung cancer pathology.
###end article-title 55
###begin article-title 56
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
###end article-title 56
###begin article-title 57
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
###end article-title 57
###begin article-title 58
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
###end article-title 58
###begin article-title 59
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
###end article-title 59
###begin article-title 60
###xml 108 116 <span type="species:ncbi:9606">patients</span>
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
###end article-title 60
###begin article-title 61
Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study.
###end article-title 61
###begin article-title 62
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
###end article-title 62
###begin article-title 63
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
###end article-title 63
###begin article-title 64
Lung cancer: intragenic ERBB2 kinase mutations in tumours.
###end article-title 64
###begin article-title 65
###xml 25 29 25 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
###end article-title 65
###begin article-title 66
###xml 48 53 <span type="species:ncbi:9606">human</span>
Somatic mutations of the ERBB4 kinase domain in human cancers.
###end article-title 66
###begin article-title 67
###xml 50 55 <span type="species:ncbi:9606">human</span>
High frequency of mutations of the PIK3CA gene in human cancers.
###end article-title 67
###begin article-title 68
###xml 39 44 <span type="species:ncbi:9606">human</span>
Missense mutations of the BRAF gene in human lung adenocarcinoma.
###end article-title 68
###begin article-title 69
###xml 26 31 <span type="species:ncbi:9606">human</span>
BRAF and RAS mutations in human lung cancer and melanoma.
###end article-title 69
###begin article-title 70
###xml 30 35 <span type="species:ncbi:9606">human</span>
Mutations of the BRAF gene in human cancer.
###end article-title 70
###begin article-title 71
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 9 15 9 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 94 98 94 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 119 127 <span type="species:ncbi:9606">patients</span>
PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.
###end article-title 71
###begin article-title 72
###xml 47 55 <span type="species:ncbi:9606">patients</span>
PIK3CA mutation status in Japanese lung cancer patients.
###end article-title 72
###begin article-title 73
Gene mutation differences in lung cancers arising in never and ever smokers.
###end article-title 73
###begin article-title 74
FGF-10 disrupts lung morphogenesis and causes pulmonary adenomas in vivo.
###end article-title 74
###begin article-title 75
Conditional expression of fibroblast growth factor-7 in the developing and mature lung.
###end article-title 75
###begin article-title 76
Phenotypic consequences of lung-specific inducible expression of FGF-3.
###end article-title 76
###begin article-title 77
PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing.
###end article-title 77
###begin article-title 78
###xml 75 80 <span type="species:ncbi:9606">human</span>
PolyScan: an automatic indel and SNP detection approach to the analysis of human re-sequencing data.
###end article-title 78
###begin article-title 79
Entrez Gene: gene-centered information at NCBI.
###end article-title 79
###begin article-title 80
Database resources of the National Center for Biotechnology Information.
###end article-title 80
###begin article-title 81
Multiple sequence alignment with the Clustal series of programs.
###end article-title 81
###begin article-title 82
CDD: a conserved domain database for interactive domain family analysis.
###end article-title 82
###begin article-title 83
Cosmic 2005.
###end article-title 83
###begin article-title 84
Base-calling of automated sequencer traces using phred. I. Accuracy assessment.
###end article-title 84
###begin article-title 85
###xml 55 60 <span type="species:ncbi:9606">human</span>
Somatic mutations of the protein kinase gene family in human lung cancer.
###end article-title 85
###begin article-title 86
Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism.
###end article-title 86
###begin article-title 87
Cellular signaling by fibroblast growth factor receptors.
###end article-title 87
###begin article-title 88
Amplification of whole tumor genomes and gene-by-gene mapping of genomic aberrations from limited sources of fresh-frozen and paraffin-embedded DNA.
###end article-title 88
###begin article-title 89
Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification.
###end article-title 89
###begin article-title 90
###xml 34 39 <span type="species:ncbi:9606">Human</span>
The Consensus Coding Sequences of Human Breast and Colorectal Cancers. Science.
###end article-title 90
###begin article-title 91
Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma.
###end article-title 91
###begin article-title 92
The new World Health Organization classification of lung tumours.
###end article-title 92
###begin title 93
Figures and Tables
###end title 93
###begin title 94
Genes sequenced in this study.
###end title 94
###begin p 95
###xml 358 366 358 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0000426.s003">Table S3</xref>
The schematic diagram depicts the EGFR signaling pathway. Genes listed in red were sequenced only in genomic DNAs from 217 tumors ("Group 1"). Genes listed in blue were sequenced only in WGA-treated DNA tumor samples ("Group 2"). Genes in black were sequenced in both groups. Gene nomenclature is as reported in GenBank as of December 2006. See Supplemental Table S3 for clinical characteristics of all tumors sequenced.
###end p 95
###begin title 96
Schematic of overall results.
###end title 96
###begin p 97
###xml 646 648 646 648 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nd</sup>
###xml 737 758 737 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0000426.s004">Supplemental Table S4</xref>
###xml 801 806 801 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERBB2</italic>
###xml 832 837 832 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAPK6</italic>
A putative variation was defined as a sequence variation compared to a reference sequence in GenBank. After visual inspection and exclusion of known SNPs and silent changes, there were 239 tumor sequences with a variation representing 174 distinct types of variations. The sequence variations were further divided into three groups: 135 variations (99 distinct types) within exons encoding the kinase domains of respective genes, 82 variations (69 types) in exons encoding areas outside the kinase domains of respective kinase genes, and 22 variations (6 types) in RAS family genes. Non-synonymous variations confirmed by sequence analysis of a 2nd PCR were either somatic mutations or variants found in matched normal tissue (listed in Supplemental Table S4). The significance of two novel variants, ERBB2 (exon 20, Arg784Cys) and MAPK6 (exon 4, Val262Ile), is unclear, because we could not determine if the variants were also found in DNA from corresponding normal tissue.
###end p 97
###begin title 98
Analysis of FGFR4.
###end title 98
###begin p 99
###xml 83 88 83 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR4</italic>
Forward/reverse sequencing chromatograms for the mutation identified in exon 16 of FGFR4 in tumor and matched normal samples. The nucleotide change is c.2041G>A, that would lead to substitution of lysine for glutamic acid at position 681.
###end p 99
###begin title 100
###xml 106 111 <span type="species:ncbi:9606">human</span>
Amino acid alignment of the FGFR4 kinase domain with other tyrosine kinase domains found to be altered in human cancers.
###end title 100
###begin p 101
###xml 599 606 599 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">methods</xref>
The DFG motif found in all kinases is underlined. The glutamic acid residue at position 681 in FGFR4 (boxed) is highly conserved amongst the various kinases. Amino acids affected by mutations and reported in the COSMIC (Catalogue of Somatic Mutations in Cancer) database appear in yellow. The analogous Glu914 residue in ERBB2 (boxed) has been found to be mutated in a glioblastoma. Figure adapted from a screenshot of the "Mutagrator" bioinformatics tool developed for this study. The previously reported Pro712Thr mutation in FGFR4 was also identified by the Mutagrator tool but is not shown. See methods for more details.
###end p 101
###begin title 102
Structural modeling of the FGFR4 Glu681Lys amino acid substitution.
###end title 102
###begin p 103
A. The FGFR4 WT and E681K mutant structures are predicted using the PROTINFO software (38) provided by the (PS)2 server (National Chiao Tung University, Taiwan). These predictions are based on crystallographic structure for FGFR1 tyrosine kinase domain (PDB accession 1FGK) (33), as no FGFR4 structure is available, and visualized using VMD (39). FGFR4 Glu681 (yellow), ATP binding site (pink), activation loop (green) and catalytic loop (white). Glu681 (yellow) is nestled between the TK activation and catalytic loops. B. 3D close-up of the surfaces of Glu681 (yellow), Arg650 (green) in the activation loop, and Ala615 (white) in the catalytic loop. Since Glu681 is strongly negatively charged and Arg650 is strongly positively charged, ionic bonding between these two closely juxtaposed residues may be assumed. C. 3D close-up of the surfaces of mutated Lys681 (orange), Arg650 and Ala615. The glutamic acid to lysine substitution at position 681 could structurally and functionally alter the kinase domain by flipping the charge of residue 681 and disrupting ionic bonds with neighboring residues, particularly the closely juxtaposed Arg650.
###end p 103
###begin title 104
###xml 28 36 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of patients whose tumors contained a somatic mutation.
###end title 104
###begin p 105
###xml 323 329 <span type="species:ncbi:9606">person</span>
Smoking history is defined as never smokers (<100 lifetime cigarettes), former smokers (quit >/=1 year prior to diagnosis), or current (quit <1 year prior to diagnosis. Former smokers were further defined as having smoked </=15 pack years (number of packs of cigarettes smoked per day multiplied by the number of years the person has smoked) or >15 pack years.
###end p 105
###begin p 106
Mutation previously reported (5).
###end p 106
###begin p 107
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 32 38 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
Tumor contained both a KRAS and PIK3CA mutation. Abbreviations: ADENO, adenocarcinoma; AWBF, adenocarcinoma with bronchioalveolar features (38); SCC, squamous cell carcinoma; dup, duplication; del, deletion. AWBF is equivalent to the WHO classification: adenocarcinoma, mixed subtype, with BAC component (39).
###end p 107
###begin title 108
###xml 22 38 22 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR, KRAS, BRAF</italic>
###xml 44 49 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR4</italic>
Mutations observed in EGFR, KRAS, BRAF, and FGFR4 in lung adenocarcinomas.
###end title 108
###begin p 109
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 56 62 56 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
Except for one KRAS mutant tumor which also contained a PIK3CA mutation, no other tumor with a mutation in one of these genes had a mutation in the other 3 genes. X denotes a mutation.
###end p 109
###begin p 110
5 EGFR mutations were previously reported (5).
###end p 110
###begin p 111
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
One KRAS mutation was found in a squamous cell carcinoma. Abbreviations: wt, wild-type.
###end p 111
###begin p 112
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 112
###begin p 113
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by the Doris Duke Charitable Foundation (WP), Joan's Legacy: The Joan Scarangello Foundation to Conquer Lung Cancer (WP), NIH K08-CA097980 (WP), the Bristol-Myers Squibb Foundation (AL), the Jodi Spiegel Fisher Cancer Foundation (WP), and The Carmel Hill Fund. WP is the incumbent of the Miner Family Chair for Intrathoracic Cancers. The funders of this study had no role in the design and conduct of the study, in the collection, analysis and interpretation of the data, or preparation and review of the manuscript.
###end p 113

